TY - JOUR
T1 - Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease
AU - Mauro, F. R.
AU - Chauvie, S.
AU - Paoloni, F.
AU - Biggi, A.
AU - Cimino, G.
AU - Rago, A.
AU - Gentile, M.
AU - Morabito, F.
AU - Coscia, M.
AU - Bellò, M.
AU - Sacchetti, G. M.
AU - Rossi, D.
AU - Laurenti, L.
AU - Autore, F.
AU - Campanelli, M.
AU - Trastulli, F.
AU - Nicolai, E.
AU - Riminucci, M.
AU - Gaidano, G.
AU - Guarini, A.
AU - Gallamini, A.
AU - Foà, R.
N1 - Publisher Copyright:
© 2015 Macmillan Publishers Limited.
PY - 2015/6/9
Y1 - 2015/6/9
N2 - In order to evaluate the predictive value of positron emission tomography-computed tomography (PET/CT) in discriminating the presence of a Richter's syndrome (RS) or a second malignancy (SM), as well as to evaluate its prognostic value in patients with chronic lymphocytic leukemia (CLL), we retrospectively analyzed the data of 90 patients who, in the suspicion of a RS or a SM, underwent PET/CT followed by the biopsy of the involved tissue. The median maximum Standardized Uptake Value (SUV max) in the presence of a CLL/small lymphocytic lymphoma, a diffuse large B-cell lymphoma (DLBCL), a Hodgkin lymphoma (HL), a SM were 3.5, 14.6, 7.0 and 6.3, respectively (P≤0.0001). A SUV max cutoff value ≥5 showed a sensitivity, specificity, positive and negative predictive values of 88.2, 71.2, 51.3 and 94%, respectively, for the presence of a more aggressive disease (DLBCL, HL and SM). A SUV max ≥5 identified also a subset of treatment naive patients with an inferior progression-free survival (P=0.011) and overall survival (P=0.067). These findings suggest that PET/CT may helpfully integrate the biologically-based prognostic stratification of CLL. Prospective clinical trials including larger cohorts of patients are needed to conclusively define the role and prognostic impact of PET/CT in the routine management of CLL patients.
AB - In order to evaluate the predictive value of positron emission tomography-computed tomography (PET/CT) in discriminating the presence of a Richter's syndrome (RS) or a second malignancy (SM), as well as to evaluate its prognostic value in patients with chronic lymphocytic leukemia (CLL), we retrospectively analyzed the data of 90 patients who, in the suspicion of a RS or a SM, underwent PET/CT followed by the biopsy of the involved tissue. The median maximum Standardized Uptake Value (SUV max) in the presence of a CLL/small lymphocytic lymphoma, a diffuse large B-cell lymphoma (DLBCL), a Hodgkin lymphoma (HL), a SM were 3.5, 14.6, 7.0 and 6.3, respectively (P≤0.0001). A SUV max cutoff value ≥5 showed a sensitivity, specificity, positive and negative predictive values of 88.2, 71.2, 51.3 and 94%, respectively, for the presence of a more aggressive disease (DLBCL, HL and SM). A SUV max ≥5 identified also a subset of treatment naive patients with an inferior progression-free survival (P=0.011) and overall survival (P=0.067). These findings suggest that PET/CT may helpfully integrate the biologically-based prognostic stratification of CLL. Prospective clinical trials including larger cohorts of patients are needed to conclusively define the role and prognostic impact of PET/CT in the routine management of CLL patients.
UR - http://www.scopus.com/inward/record.url?scp=84930574902&partnerID=8YFLogxK
U2 - 10.1038/leu.2015.21
DO - 10.1038/leu.2015.21
M3 - Article
SN - 0887-6924
VL - 29
SP - 1360
EP - 1365
JO - Leukemia
JF - Leukemia
IS - 6
ER -
